» Articles » PMID: 18098298

Diagnostic Procedures for Parkinson's Disease Dementia: Recommendations from the Movement Disorder Society Task Force

Abstract

A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time-consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD-D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD-D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence-based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies.

Citing Articles

Contribution of fatigue experienced by Parkinson's Disease patients on caregiver burden.

Landolfo S, Urso D, Santoro C, Batzu L, Gnoni V, Giugno A J Neurol. 2025; 272(4):264.

PMID: 40072620 DOI: 10.1007/s00415-025-12962-z.


Subregion-specific associations of the basal forebrain with sleep and cognition in Parkinson's disease.

Lee J, Kim H, Ahn S, Park M, Yoo H, Lyoo C NPJ Parkinsons Dis. 2025; 11(1):33.

PMID: 39979309 PMC: 11842645. DOI: 10.1038/s41531-025-00880-w.


Propranolol Reduces Parkinson's Tremor and Inhibits Tremor-Related Activity in the Motor Cortex: A Placebo-Controlled Crossover Trial.

van der Heide A, Wessel M, Papadopetraki D, Geurts D, van Prooije T, Gommans F Ann Neurol. 2024; 97(4):741-752.

PMID: 39707791 PMC: 11889531. DOI: 10.1002/ana.27159.


Brain-derived and in vitro-seeded alpha-synuclein fibrils exhibit distinct biophysical profiles.

Lee S, Civitelli L, Parkkinen L Elife. 2024; 13.

PMID: 39584804 PMC: 11588339. DOI: 10.7554/eLife.92775.


Efficacy and safety of hyperbaric oxygen therapy for Parkinson's disease with cognitive dysfunction: protocol for a systematic review and meta-analysis.

Tan W, Pan Z, Xie F BMJ Open. 2024; 14(11):e087164.

PMID: 39572094 PMC: 11580330. DOI: 10.1136/bmjopen-2024-087164.